Modified FOLFIRINOX for advanced pancreatic cancer : a tertiary center experience from China
OBJECTIVE: To explore efficacy and safety of modified FOLFIRINOX (mFOLFIRINOX) regimen by dose attenuation in locally advanced pancreatic cancer (LAPC) and metastatic pancreatic cancer(MPC).
METHODS: Between April 2014 and October 2015, 35 patients with LAPC (n=18) or MPC (n=17) were treated with mFOLFIRINOX regimen (irinotecan 135 mg/m(2), oxaliplatin 68 mg/m(2), 5-FU 2 400 mg/m(2), no bolus of 5-FU, leucovorin 400 mg/m(2)) in the Second Affiliated Hospital of Zhejiang University School of Medicine. The primary end point was progression free survival. The second end points were overall survival, objective response rate, adverse effects, surgical resection rate for LAPC.
RESULTS: Among 35 patients, 6 patients (17.1%) who dropped out and received less than 2 cycles were excluded for response analysis. Among the other 29 patients, 9 patients had grade 3 or 4 adverse effects. No patients ceased treatment due to adverse effects. The 29 patients received 5 (2-13) cycles were evaluated by efficacy and found partial remission in 16 cases, stable disease in 10 cases, progression disease in 3 cases. Response rate was 55.2%. Nine patients with LAPC accomplished surgery after neoadjuvant treatment without perioperative complication and death, and 6 patients accepted R0 resection.
CONCLUSIONS: The mFOLFIRINOX regimen used in the study is well-tolerated in Chinese population with high treatment efficacy on patients with LAPC and MPC. Further investigation of efficacy and adverse effects on more advanced pancreatic cancer patients is necessary.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Zhonghua wai ke za zhi [Chinese journal of surgery - 54(2016), 4 vom: 01. Apr., Seite 270-5 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Bai, Xueli [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
04ZR38536J |
|---|
| Anmerkungen: |
Date Completed 15.09.2016 Date Revised 02.12.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.issn.0529-5815.2016.04.006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM258926562 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM258926562 | ||
| 003 | DE-627 | ||
| 005 | 20231224190057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.issn.0529-5815.2016.04.006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0863.xml |
| 035 | |a (DE-627)NLM258926562 | ||
| 035 | |a (NLM)27029201 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Bai, Xueli |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Modified FOLFIRINOX for advanced pancreatic cancer |b a tertiary center experience from China |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2016 | ||
| 500 | |a Date Revised 02.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: To explore efficacy and safety of modified FOLFIRINOX (mFOLFIRINOX) regimen by dose attenuation in locally advanced pancreatic cancer (LAPC) and metastatic pancreatic cancer(MPC) | ||
| 520 | |a METHODS: Between April 2014 and October 2015, 35 patients with LAPC (n=18) or MPC (n=17) were treated with mFOLFIRINOX regimen (irinotecan 135 mg/m(2), oxaliplatin 68 mg/m(2), 5-FU 2 400 mg/m(2), no bolus of 5-FU, leucovorin 400 mg/m(2)) in the Second Affiliated Hospital of Zhejiang University School of Medicine. The primary end point was progression free survival. The second end points were overall survival, objective response rate, adverse effects, surgical resection rate for LAPC | ||
| 520 | |a RESULTS: Among 35 patients, 6 patients (17.1%) who dropped out and received less than 2 cycles were excluded for response analysis. Among the other 29 patients, 9 patients had grade 3 or 4 adverse effects. No patients ceased treatment due to adverse effects. The 29 patients received 5 (2-13) cycles were evaluated by efficacy and found partial remission in 16 cases, stable disease in 10 cases, progression disease in 3 cases. Response rate was 55.2%. Nine patients with LAPC accomplished surgery after neoadjuvant treatment without perioperative complication and death, and 6 patients accepted R0 resection | ||
| 520 | |a CONCLUSIONS: The mFOLFIRINOX regimen used in the study is well-tolerated in Chinese population with high treatment efficacy on patients with LAPC and MPC. Further investigation of efficacy and adverse effects on more advanced pancreatic cancer patients is necessary | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Organoplatinum Compounds |2 NLM | |
| 650 | 7 | |a Oxaliplatin |2 NLM | |
| 650 | 7 | |a 04ZR38536J |2 NLM | |
| 650 | 7 | |a Irinotecan |2 NLM | |
| 650 | 7 | |a 7673326042 |2 NLM | |
| 650 | 7 | |a Leucovorin |2 NLM | |
| 650 | 7 | |a Q573I9DVLP |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 650 | 7 | |a Camptothecin |2 NLM | |
| 650 | 7 | |a XT3Z54Z28A |2 NLM | |
| 700 | 1 | |a Su, Riga |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Shichao |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Guogang |e verfasserin |4 aut | |
| 700 | 1 | |a Lou, Jianying |e verfasserin |4 aut | |
| 700 | 1 | |a Gao, Shunliang |e verfasserin |4 aut | |
| 700 | 1 | |a Que, Risheng |e verfasserin |4 aut | |
| 700 | 1 | |a Yuan, Ying |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Risheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Qichun |e verfasserin |4 aut | |
| 700 | 1 | |a Liang, Tingbo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua wai ke za zhi [Chinese journal of surgery |d 1957 |g 54(2016), 4 vom: 01. Apr., Seite 270-5 |w (DE-627)NLM000467634 |x 0529-5815 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2016 |g number:4 |g day:01 |g month:04 |g pages:270-5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.issn.0529-5815.2016.04.006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2016 |e 4 |b 01 |c 04 |h 270-5 | ||